Literature DB >> 34236488

Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome.

Shekhar Gogna1, David Samson1, Mahir Gachabayov1, Aram Rojas1, Daniel Moritz Felsenreich2, Donna Koo3, Katie Gu4, Luis Quintero3, Kendall Ryan Miller4, Asad Azim1, Xiang Da Eric Dong5,6.   

Abstract

PURPOSE: Neuroendocrine neoplasms (NENs) of the gallbladder are very rare. As a result, the classification of pathologic specimens from gallbladder NENs, currently classified as gallbladder neuroendocrine tumors (GB-NETs) and carcinomas (GB-NECs), is inconsistent and makes nomenclature, classification, and management difficult. Our study aims to evaluate the epidemiological trend, tumor biology, and outcomes of GB-NET and GB-NEC over the last 5 decades.
METHODS: This is a retrospective analysis of the SEER database from 1973 to 2016. The epidemiological trend was analyzed using the age-adjusted Joinpoint regression analysis. Survival was assessed with Kaplan-Meier analysis and Cox regression was used to assess predictors of poor survival.
RESULTS: A total of 482 patients with GB-NEN were identified. Mean age at diagnosis was 65.2 ± 14.3 years. Females outnumbered males (65.6% vs. 34.4%). The Joinpoint nationwide trend analysis showed a 7% increase per year from 1973 to 2016. The mean survival time after diagnosis of GB-NEN was 37.11 ± 55.3 months. The most common pattern of nodal distribution was N0 (50.2%) followed by N1 (30.9%) and N2 (19.2%). Advanced tumor spread (into the liver, regional, and distant metastasis) was seen in 60.3% of patients. Patients who underwent surgery had a significant survival advantage (111.0 ± 8.3 vs. 8.3 ± 1.2 months, p < 0.01). Cox regression analysis showed advanced age (p < 0.01), tumor stage (P < 0.01), tumor extension (p < 0.01), and histopathologic grade (p < 0.01) were associated with higher mortality.
CONCLUSION: Gallbladder NENs are a rare histopathological variant of gallbladder cancer that is showing a rising incidence in the USA. In addition to tumor staging, surgical resection significantly impacts patient survival, when patients are able to undergo surgery irrespective of tumor staging. Advanced age, tumor extension, and histopathological grade of the tumor were associated with higher mortality.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Carcinoid tumor; Epidemiology; Gallbladder cancer; Neuroendocrine carcinomas; Neuroendocrine neoplasms; Neuroendocrine tumors

Mesh:

Year:  2021        PMID: 34236488     DOI: 10.1007/s00423-021-02256-z

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  24 in total

1.  Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  K Oberg; G Akerström; G Rindi; S Jelic
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.

Authors:  George C Nikou; N J Lygidakis; Christos Toubanakis; Spiridon Pavlatos; Sofia Tseleni-Balafouta; Eleanna Giannatou; Elias Mallas; Michael Safioleas
Journal:  Hepatogastroenterology       Date:  2005 May-Jun

Review 3.  An analysis of rare carcinoid tumors: clarifying these clinical conundrums.

Authors:  Irvin M Modlin; Michael D Shapiro; Mark Kidd
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

Review 4.  The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept.

Authors:  A G Pearse
Journal:  J Histochem Cytochem       Date:  1969-05       Impact factor: 2.479

Review 5.  Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases.

Authors:  J Soga
Journal:  J Exp Clin Cancer Res       Date:  2003-12

Review 6.  Neuroendocrine tumors of the diffuse neuroendocrine system.

Authors:  Björn I Gustafsson; Mark Kidd; Irvin M Modlin
Journal:  Curr Opin Oncol       Date:  2008-01       Impact factor: 3.645

Review 7.  Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Mauro Cives; Jonathan R Strosberg
Journal:  CA Cancer J Clin       Date:  2018-10-08       Impact factor: 508.702

8.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

9.  The 2019 WHO classification of tumours of the digestive system.

Authors:  Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

10.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.